Corneal thinning drug approved in US

A new drug for the treatment of eyes is approved in the USA. The developer was Glaukos Corporation. Patients will have a less painful treatment option for a progressive disease.

Thanks to the approval of a new drug called Epioxa, the traditional removal of the eye's outer protective layer, the corneal epithelium, will no longer be necessary, writes xrust. The drug is approved to treat keratoconus, a condition in which the cornea thins and changes shape over time.

This causes blurred vision and increases the risk of blindness. The new product will go on sale in the first of the coming year.

Recall that the first generation drug iLink from Photrexa, approved in 2016, has so far been the only offer. Its disadvantage is that it requires an epi-off approach, in which the doctor removes the outer layer of the cornea. This increases the risk of complications and delays recovery.

Keratoconus affects approximately one in 2,000 people and usually begins during puberty and progresses thereafter. Standard treatment is glasses, hard contact lenses and corneal surgery.

Xrust Corneal thinning drug approved in the US